The 14 analysts offering 12-month price forecasts for Horizon Therapeutics PLC have a median target of 99.50, with a high estimate of 146.00 and a low estimate of 74.00. The median estimate represents a +26.29% increase from the last price of 78.79.
The current consensus among 14 polled investment analysts is to Buy stock in Horizon Therapeutics PLC. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $1.07
Reporting Date Mar 01
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.